Global Paliperidone Palmitate Therapeutic Injection 麻豆原创 Research Report 2025

Publication ID:

PB505250160

Publication Date:

May 6, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Paliperidone Palmitate Therapeutic Injection was valued at US$ 4100 million in the year 2024 and is projected to reach a revised size of US$ 6262 million by 2031, growing at a CAGR of 6.3% during the forecast period.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Paliperidone Palmitate Therapeutic Injection competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Paliperidone palmitate therapeutic injection is a long-acting sustained-release antipsychotic drug, the main ingredient of which is paliperidone palmitate. It is administered by intramuscular injection and can gradually release the drug in the body to achieve a sustained and stable therapeutic effect. The injection is mainly used to treat schizophrenia and schizoaffective disorder, helping to improve patients' symptoms, reduce relapse rates, and improve medication compliance. It is particularly suitable for patients who need long-term maintenance treatment.
North American market for Paliperidone Palmitate Therapeutic Injection is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Paliperidone Palmitate Therapeutic Injection is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Paliperidone Palmitate Therapeutic Injection include Janssen Pharmaceuticals, Teva Pharmaceutical, Viatris, Sun Pharmaceutical, Cipla, Hikma Pharmaceuticals, Qilu Pharmaceutical, Hansoh Pharmaceuticak Group, Luye Pharma Group, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Paliperidone Palmitate Therapeutic Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Paliperidone Palmitate Therapeutic Injection.
The Paliperidone Palmitate Therapeutic Injection market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Paliperidone Palmitate Therapeutic Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Paliperidone Palmitate Therapeutic Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Janssen Pharmaceuticals
Teva Pharmaceutical
Viatris
Sun Pharmaceutical
Cipla
Hikma Pharmaceuticals
Qilu Pharmaceutical
Hansoh Pharmaceuticak Group
Luye Pharma Group
Segment by Type
Monthly Dosage Form
Quarterly Dosage Form
Segment by Application
General Hospital
Specialized Hospital
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Paliperidone Palmitate Therapeutic Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Paliperidone Palmitate Therapeutic Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Paliperidone Palmitate Therapeutic Injection 麻豆原创 Overview
1.1 Product Definition
1.2 Paliperidone Palmitate Therapeutic Injection by Type
1.2.1 Global Paliperidone Palmitate Therapeutic Injection 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 Monthly Dosage Form
1.2.3 Quarterly Dosage Form
1.3 Paliperidone Palmitate Therapeutic Injection by Application
1.3.1 Global Paliperidone Palmitate Therapeutic Injection 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 General Hospital
1.3.3 Specialized Hospital
1.3.4 Others
1.4 Global Paliperidone Palmitate Therapeutic Injection 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Paliperidone Palmitate Therapeutic Injection Revenue 2020-2031
1.4.2 Global Paliperidone Palmitate Therapeutic Injection Sales 2020-2031
1.4.3 Global Paliperidone Palmitate Therapeutic Injection 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Paliperidone Palmitate Therapeutic Injection 麻豆原创 Competition by Manufacturers
2.1 Global Paliperidone Palmitate Therapeutic Injection Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Paliperidone Palmitate Therapeutic Injection Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Paliperidone Palmitate Therapeutic Injection Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Paliperidone Palmitate Therapeutic Injection, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Paliperidone Palmitate Therapeutic Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Paliperidone Palmitate Therapeutic Injection, Product Type & Application
2.7 Global Key Manufacturers of Paliperidone Palmitate Therapeutic Injection, Date of Enter into This Industry
2.8 Global Paliperidone Palmitate Therapeutic Injection 麻豆原创 Competitive Situation and Trends
2.8.1 Global Paliperidone Palmitate Therapeutic Injection 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Paliperidone Palmitate Therapeutic Injection Players 麻豆原创 Share by Revenue
2.8.3 Global Paliperidone Palmitate Therapeutic Injection Company Type and 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Paliperidone Palmitate Therapeutic Injection 麻豆原创 Scenario by Region
3.1 Global Paliperidone Palmitate Therapeutic Injection 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Paliperidone Palmitate Therapeutic Injection Sales by Region: 2020-2031
3.2.1 Global Paliperidone Palmitate Therapeutic Injection Sales by Region: 2020-2025
3.2.2 Global Paliperidone Palmitate Therapeutic Injection Sales by Region: 2026-2031
3.3 Global Paliperidone Palmitate Therapeutic Injection Revenue by Region: 2020-2031
3.3.1 Global Paliperidone Palmitate Therapeutic Injection Revenue by Region: 2020-2025
3.3.2 Global Paliperidone Palmitate Therapeutic Injection Revenue by Region: 2026-2031
3.4 North America Paliperidone Palmitate Therapeutic Injection 麻豆原创 Facts & Figures by Country
3.4.1 North America Paliperidone Palmitate Therapeutic Injection 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Paliperidone Palmitate Therapeutic Injection Sales by Country (2020-2031)
3.4.3 North America Paliperidone Palmitate Therapeutic Injection Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Paliperidone Palmitate Therapeutic Injection 麻豆原创 Facts & Figures by Country
3.5.1 Europe Paliperidone Palmitate Therapeutic Injection 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Paliperidone Palmitate Therapeutic Injection Sales by Country (2020-2031)
3.5.3 Europe Paliperidone Palmitate Therapeutic Injection Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Paliperidone Palmitate Therapeutic Injection 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Paliperidone Palmitate Therapeutic Injection 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Paliperidone Palmitate Therapeutic Injection Sales by Region (2020-2031)
3.6.3 Asia Pacific Paliperidone Palmitate Therapeutic Injection Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Paliperidone Palmitate Therapeutic Injection 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Paliperidone Palmitate Therapeutic Injection 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Paliperidone Palmitate Therapeutic Injection Sales by Country (2020-2031)
3.7.3 Latin America Paliperidone Palmitate Therapeutic Injection Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Paliperidone Palmitate Therapeutic Injection 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Paliperidone Palmitate Therapeutic Injection 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Paliperidone Palmitate Therapeutic Injection Sales by Country (2020-2031)
3.8.3 Middle East and Africa Paliperidone Palmitate Therapeutic Injection Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Paliperidone Palmitate Therapeutic Injection Sales by Type (2020-2031)
4.1.1 Global Paliperidone Palmitate Therapeutic Injection Sales by Type (2020-2025)
4.1.2 Global Paliperidone Palmitate Therapeutic Injection Sales by Type (2026-2031)
4.1.3 Global Paliperidone Palmitate Therapeutic Injection Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Paliperidone Palmitate Therapeutic Injection Revenue by Type (2020-2031)
4.2.1 Global Paliperidone Palmitate Therapeutic Injection Revenue by Type (2020-2025)
4.2.2 Global Paliperidone Palmitate Therapeutic Injection Revenue by Type (2026-2031)
4.2.3 Global Paliperidone Palmitate Therapeutic Injection Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Paliperidone Palmitate Therapeutic Injection Price by Type (2020-2031)
5 Segment by Application
5.1 Global Paliperidone Palmitate Therapeutic Injection Sales by Application (2020-2031)
5.1.1 Global Paliperidone Palmitate Therapeutic Injection Sales by Application (2020-2025)
5.1.2 Global Paliperidone Palmitate Therapeutic Injection Sales by Application (2026-2031)
5.1.3 Global Paliperidone Palmitate Therapeutic Injection Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Paliperidone Palmitate Therapeutic Injection Revenue by Application (2020-2031)
5.2.1 Global Paliperidone Palmitate Therapeutic Injection Revenue by Application (2020-2025)
5.2.2 Global Paliperidone Palmitate Therapeutic Injection Revenue by Application (2026-2031)
5.2.3 Global Paliperidone Palmitate Therapeutic Injection Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Paliperidone Palmitate Therapeutic Injection Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Janssen Pharmaceuticals
6.1.1 Janssen Pharmaceuticals Company Information
6.1.2 Janssen Pharmaceuticals Description and Business Overview
6.1.3 Janssen Pharmaceuticals Paliperidone Palmitate Therapeutic Injection Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Janssen Pharmaceuticals Paliperidone Palmitate Therapeutic Injection Product Portfolio
6.1.5 Janssen Pharmaceuticals Recent Developments/Updates
6.2 Teva Pharmaceutical
6.2.1 Teva Pharmaceutical Company Information
6.2.2 Teva Pharmaceutical Description and Business Overview
6.2.3 Teva Pharmaceutical Paliperidone Palmitate Therapeutic Injection Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Teva Pharmaceutical Paliperidone Palmitate Therapeutic Injection Product Portfolio
6.2.5 Teva Pharmaceutical Recent Developments/Updates
6.3 Viatris
6.3.1 Viatris Company Information
6.3.2 Viatris Description and Business Overview
6.3.3 Viatris Paliperidone Palmitate Therapeutic Injection Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Viatris Paliperidone Palmitate Therapeutic Injection Product Portfolio
6.3.5 Viatris Recent Developments/Updates
6.4 Sun Pharmaceutical
6.4.1 Sun Pharmaceutical Company Information
6.4.2 Sun Pharmaceutical Description and Business Overview
6.4.3 Sun Pharmaceutical Paliperidone Palmitate Therapeutic Injection Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Sun Pharmaceutical Paliperidone Palmitate Therapeutic Injection Product Portfolio
6.4.5 Sun Pharmaceutical Recent Developments/Updates
6.5 Cipla
6.5.1 Cipla Company Information
6.5.2 Cipla Description and Business Overview
6.5.3 Cipla Paliperidone Palmitate Therapeutic Injection Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Cipla Paliperidone Palmitate Therapeutic Injection Product Portfolio
6.5.5 Cipla Recent Developments/Updates
6.6 Hikma Pharmaceuticals
6.6.1 Hikma Pharmaceuticals Company Information
6.6.2 Hikma Pharmaceuticals Description and Business Overview
6.6.3 Hikma Pharmaceuticals Paliperidone Palmitate Therapeutic Injection Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Hikma Pharmaceuticals Paliperidone Palmitate Therapeutic Injection Product Portfolio
6.6.5 Hikma Pharmaceuticals Recent Developments/Updates
6.7 Qilu Pharmaceutical
6.7.1 Qilu Pharmaceutical Company Information
6.7.2 Qilu Pharmaceutical Description and Business Overview
6.7.3 Qilu Pharmaceutical Paliperidone Palmitate Therapeutic Injection Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Qilu Pharmaceutical Paliperidone Palmitate Therapeutic Injection Product Portfolio
6.7.5 Qilu Pharmaceutical Recent Developments/Updates
6.8 Hansoh Pharmaceuticak Group
6.8.1 Hansoh Pharmaceuticak Group Company Information
6.8.2 Hansoh Pharmaceuticak Group Description and Business Overview
6.8.3 Hansoh Pharmaceuticak Group Paliperidone Palmitate Therapeutic Injection Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Hansoh Pharmaceuticak Group Paliperidone Palmitate Therapeutic Injection Product Portfolio
6.8.5 Hansoh Pharmaceuticak Group Recent Developments/Updates
6.9 Luye Pharma Group
6.9.1 Luye Pharma Group Company Information
6.9.2 Luye Pharma Group Description and Business Overview
6.9.3 Luye Pharma Group Paliperidone Palmitate Therapeutic Injection Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Luye Pharma Group Paliperidone Palmitate Therapeutic Injection Product Portfolio
6.9.5 Luye Pharma Group Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Paliperidone Palmitate Therapeutic Injection Industry Chain Analysis
7.2 Paliperidone Palmitate Therapeutic Injection Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Paliperidone Palmitate Therapeutic Injection Production Mode & Process Analysis
7.4 Paliperidone Palmitate Therapeutic Injection Sales and 麻豆原创ing
7.4.1 Paliperidone Palmitate Therapeutic Injection Sales Channels
7.4.2 Paliperidone Palmitate Therapeutic Injection Distributors
7.5 Paliperidone Palmitate Therapeutic Injection Customer Analysis
8 Paliperidone Palmitate Therapeutic Injection 麻豆原创 Dynamics
8.1 Paliperidone Palmitate Therapeutic Injection Industry Trends
8.2 Paliperidone Palmitate Therapeutic Injection 麻豆原创 Drivers
8.3 Paliperidone Palmitate Therapeutic Injection 麻豆原创 Challenges
8.4 Paliperidone Palmitate Therapeutic Injection 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Janssen Pharmaceuticals
Teva Pharmaceutical
Viatris
Sun Pharmaceutical
Cipla
Hikma Pharmaceuticals
Qilu Pharmaceutical
Hansoh Pharmaceuticak Group
Luye Pharma Group

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.